The Clostridioides difficile Infections (Clostridium difficile Associated Disease) drugs in development market research report provides comprehensive information on the therapeutics under development ...

Study finds underutilization of fidaxomicin, a recommended treatment for C. diff infection, despite increased use in hospitals.

The results from the open label phase 2 trial confirm that Rebiotix’s drug, RBX2660, is the frontrunner among a coming wave of new microbiome treatments. The Minnesota-based company is focused ...

diff, reducing and hopefully eradicating the infection. Ferring acquired the drug along with its developer Rebiotix in 2018. Ferring and Rebiotix are only releasing the top-line message from the ...

Biopharmaceutical company Crestone Pharmaceuticals last week announced positive topline results from a phase 2 trial of its investigational drug treatment for Clostridioides difficile infection (CDI).

Updated guidelines recommend fidaxomicin as the first-line agent for C difficile infection, but researchers found use in US ...

An mRNA vaccine that targets several aspects of C. difficile’s ability to cause severe disease prevented major symptoms and death in mice.

Could Taking Certain Drugs Reduce Risk of Ruptured Brain Aneurysm? June 5, 2024 — A new study suggests that people who take a few common drugs may have a decreased risk of having a bleeding ...

Clostridium difficile colitis (CDC) is an infection of the intestine caused by the bacteria Clostridioides difficile. Symptoms may be mild, but life-threatening complications can develop. Those at ...